Besides ovarian cancer, olaparib has also shown potential efficacy in other cancers involving both germline and somatic BRCA1/2 mutations, including that of prostate, breast, gastric and pancreatic cancer [3,22,23]. Here, BRCA1 is linked to ovarian carcinoma.